Q4 EPS Estimate for United Therapeutics Lifted by Analyst

United Therapeutics Co. (NASDAQ:UTHR) – Equities research analysts at Zacks Research lifted their Q4 2024 EPS estimates for shares of United Therapeutics in a research report issued to clients and investors on Tuesday, November 19th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings per share of $6.04 for the quarter, up from their prior estimate of $5.40. The consensus estimate for United Therapeutics’ current full-year earnings is $25.10 per share. Zacks Research also issued estimates for United Therapeutics’ Q3 2025 earnings at $7.33 EPS, Q4 2025 earnings at $6.74 EPS, FY2025 earnings at $27.64 EPS, Q3 2026 earnings at $7.15 EPS and FY2026 earnings at $26.89 EPS.

A number of other analysts have also recently weighed in on the stock. Argus raised their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. HC Wainwright increased their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. TD Cowen increased their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Bank of America reduced their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Stock Performance

Shares of UTHR opened at $367.36 on Friday. United Therapeutics has a 1 year low of $208.62 and a 1 year high of $417.82. The company’s 50-day simple moving average is $364.39 and its 200-day simple moving average is $330.59. The stock has a market capitalization of $16.40 billion, a PE ratio of 16.13, a P/E/G ratio of 1.05 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue was up 22.9% on a year-over-year basis. During the same period in the previous year, the company posted $5.38 earnings per share.

Insider Activity

In related news, Director Judy D. Olian sold 1,750 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $412.48, for a total value of $721,840.00. Following the sale, the director now directly owns 5,655 shares in the company, valued at $2,332,574.40. The trade was a 23.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $45,293.30. The trade was a 67.42 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 109,796 shares of company stock valued at $40,936,370. 11.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently bought and sold shares of the business. ClariVest Asset Management LLC boosted its stake in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC acquired a new position in shares of United Therapeutics in the 2nd quarter worth approximately $30,000. Innealta Capital LLC acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at $33,000. USA Financial Formulas acquired a new stake in shares of United Therapeutics during the third quarter worth approximately $33,000. Finally, Brooklyn Investment Group bought a new stake in shares of United Therapeutics during the third quarter worth $33,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.